| Literature DB >> 32396622 |
Ariel Izcovich1, Adam Cuker2,3, Robert Kunkle4, Ignacio Neumann5,6, Julie Panepinto7, Menaka Pai8, Matthew Seftel9, Matthew C Cheung10, Richard Lottenberg11, Michael Byrne12, Robert Plovnick4, Deirdra Terrell13, Jennifer L Holter-Chakrabarty14, Benjamin Djulbegovic15,16, Lisa K Hicks17,18, Wojtek Wiercioch19,20,21, Robby Nieuwlaat19,20,21, Holger J Schünemann8,19,20,21.
Abstract
Since November 2018, Blood Advances has published American Society of Hematology (ASH) clinical practice guidelines on venous thromboembolism, immune thrombocytopenia, and sickle cell disease. More ASH guidelines on these and other topics are forthcoming. These guidelines have been developed using consistent processes, methods, terminology, and presentation formats. In this article, we describe how patients, clinicians, policymakers, researchers, and others may use ASH guidelines and the many related derivates by describing how to interpret information and how to apply it to clinical decision-making. Also, by exploring how these documents are developed, we aim to clarify their limitations and possible inappropriate usage.Entities:
Mesh:
Year: 2020 PMID: 32396622 PMCID: PMC7218428 DOI: 10.1182/bloodadvances.2020001755
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529